← All trials
NCT01504815
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2012
- Primary completion
- Nov 1, 2017
- Completion date
- Mar 1, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 268
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Netherlands Cancer InstituteLead sponsor
- Netherlands Cancer InstituteOverall official - principal investigator
- The Christie NHS Foundation TrustCollaborator
- Utrecht UniversityCollaborator
- Maastricht UniversityCollaborator
- Institut Catala de SalutCollaborator
- European UnionCollaborator
- Institut Gustave RoussyCollaborator
- Karolinska InstituteCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.